Sign In   |   Register

 

Breaking News:

Breaking News

Trickle Research issues update and allocation increase to 7
AzurRx Biopharma, Inc.  7-11-19
12-24 Month Price Target $10.25

Click Here for Update Report

6-6-19 Greenridge Global Equity Research
Issues Update
Guangdong Land Holdings, Ltd.
Maintaining rating and Buy target HK$ 4.75
Click Here>>

6-4-19 Trickle Research Issues Allocation Update Report
Summit Wireless Technologies, Inc. Nasdaq (WISA) 
12-24 Month Price Target $9.25

Allocation 5
Click Here>>

4-9-19 Trickle Research Initiates Research
H Source Holdings, Ltd., TSXV (HSI.V) OTCQB (HSCHF) 
12-24 Month Price Target $0.19
Click Here>>

5-20-18 Trickle Research Issues Update Report
Alvopetro Energy, Ltd., TSXV (ALV.V) OTC (ALVOF) 
12-24 Month Price Target $1.10
Clcik Here>>

4-29-19 Greenridge Global Equity Research Issues Updates
Guangdong Land Holdings, Ltd.
Click Here>>

Chardan Research Earnings Update 4-19-19
  Social Reality Inc. (SRAX)
Target Price $10.00

Click Here for Report

4-17-19 Canbiola, Inc. (CANB)
Canbiola Announces Fourth Quarter and Full Year 2018 Results

Click Here for Complete Release

Trickle Research Earnings Update 4-16-19
  Social Reality Inc. (SRAX)
12-24 Month Target Price $15.00

Click Here for Report

Trickle Research Fiscal 2018
Earnings
& Merger Announcement Update Update 4-10-19
12-24 Month Target Price $8.75

Click Here for Report

3-28-2019 Endurance Exploration Group, Inc. (EXPL)

Blue Water Ventures International, Inc. and Project Partner Endurance Exploration Group, Inc. Announce Preparations for 2019 Operations

Read Complete Press Release>>

3-11-19 Canbiola, Inc. (CANB) Canbiola is Registered and Active in the GSA’s System for Award Management (SAM) and Department of Defense (DOD)
Read Complete Press Release>>

Trickle Research issues update of
AzurRx Biopharma, Inc.  2-26-19
12-24 Month Price Target $10.25

Click Here for Update Report

Trickle Research Earnings Update 2-9-19
  Social Reality Inc. (SRAX)
12-24 Month Target Price $9.25

Click Here for Report

 


 





 

  Black Swan Research
Research Coverage 4-19
SMM is now hosting Equity Research and updates from top tier research providers:           
 Trickle Research
Click here to Subscribe to Trickle Research 
 Falcon Strategic Research
 Consilium Global Research
 ValuEngine
 Click Here to Subscribe to Black Swan Research
              

Black Swan Newsletter

SUBSCRIBE TO THE NEWSLETTER BELOW






 

July 2019

Click here to view

Our goal with the Black Swan Connection is to provide our subscribers, investors and financial professional compatriots outstanding investment insight that is a step above and outside of what will normally be found in mainstream financial press. To that end we have brought together seasoned, successful, and some of the brightest professionals in their respective fields to provide the articles and advice that is based on decades of practice in the field.

Breaking News

The Street July 16-2019

What Jim Cramer's Paying Attention to in JPMorgan Chase's Earnings Report

Earnings season has officially kicked off. 

Tuesday morning saw earnings from banks such as Real Money stock of the day JPMorgan Chase (JPM - Get Report) and Goldman Sachs (GS - Get Report) . 

JPMorgan reported that net income in the quarter rose by 16% to $9.65 billion. The company announced earnings per share at $2.82, which beat the $2.50 average EPS estimate that analysts expected, according to FactSet.

See Report

 

Feature Article

July 2019

The Unintended Consequences of Chaos

By: Dave Lavigne

It’s fascinating how sometimes seemingly unrelated things create a web of complexities that ultimately demonstrate how interrelated things might actually be. I think that notion falls into the guise of Chaos Theory or at least some portion of it.

Just to edify, www.fractalfoundation.org defines Chaos Theory as follows:

“Chaos is the science of surprises, of the nonlinear and the unpredictable. It teaches us to expect the unexpected. While most traditional science deals with supposedly predictable phenomena like gravity, electricity, or chemical reactions, Chaos Theory deals with nonlinear things that are effectively impossible to predict or control, like turbulence, weather, the stock market, our brain states, and so on. These phenomena are often described by fractal mathematics, which captures the infinite complexity of nature. Many natural objects exhibit fractal properties, including landscapes, clouds, trees, organs, rivers etc, and many of the systems in which we live exhibit complex, chaotic behavior. Recognizing the chaotic, fractal nature of our world can give us new insight, power, and wisdom. For example, by understanding the complex, chaotic dynamics of the atmosphere, a balloon pilot can “steer” a balloon to a desired location. By understanding that our ecosystems, our social systems, and our economic systems are interconnected, we can hope to avoid actions which may end up being detrimental to our long-term well-being”.  

As an adjunct to the above, some may be more familiar with one of Chaos’s often used examples:  “Does the flap of a butterfly’s wings in Brazil set off a tornado in Texas”?

Read Complete Article

InvestorsHub News Wire:

 

 

Weekly Update: Aug 6th, 2019

Breaking News

Yahoo Finance Aug-6-19
Why investors should get used to market volatility

The ongoing U.S.-China trade war has evolved into a currency war with markets moving off their worst day of the year. Yahoo Finance's Julie Hyman, Adam Shapiro, Sibile Marcellus, David Kotok of Cumberland Advisors and Ron Weiner - RDM Financial Group at HighTower Managing Director and Partner discuss.

Read Complete Article

 

8-2-19 Canbiola, Inc. (OTCQB:CANB)

Canbiola Launches Dedicated Canbiola-Branded CBD Dispensing Machine

Initial 25 Units Will Target Medical Offices

HICKSVILLE, NY, Aug. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the “Company”), a developer, manufacturer, and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, isolate, gel caps, and concentrate announced today the launch of its own Canbiola-branded CBD product dispensing machine. An initial order for the first 25 units has been placed with the installations expected to occur in August and September.

Read Complete Press Release

 

7-16-19 Antibe Therapeutics, Inc. TSXV:ATE, OTCQB:ATBPF)

Antibe Therapeutics Reports 2019 Year-End Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF) filed its financial and operating results on Tuesday, July 16 for the fourth quarter and the year ended March 31, 2019. The Company's audited 2019 consolidated financial statements, MD&A and AIF are available on SEDAR.

About Antibe Therapeutics Inc.
Antibe develops safer, non-addictive medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation.

Read Complete Press Release

 

7-11-19 Trickle Research issues update and allocation increase to 7
AzurRx Biopharma, Inc.  NASDAQ AZRX
12-24 Month Price Target $10.25

AZRX made the following announcement the other day regarding a new clinical trial they are preparing. They also hosted a call to discuss the logic behind the trial. Here is that release: AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

  • Dose escalation study of MS1819-SD in combination with standard porcine pancreatic enzyme replacement therapy (PERT) in CF patients with severe exocrine pancreatic insufficiency (EPI)
  • .Patients in study have persistent malnutrition and clinical symptoms of fat malabsorption despite being on the maximum daily doses of PERTs.
  • First patient visits have been completed in Hungary.
  • Preliminary data expected in early 2020.

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) --AzurRx BioPharma, Inc. (AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has initiated a Phase 2 clinical trial to investigate MS1819-SD in combination with standard porcine enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF) that suffer from severe exocrine pancreatic insufficiency (EPI), but continue to experience clinical symptoms of fat malabsorption despite taking the maximum daily dose of PERTs.

Read Complete Report

Community Search
Sign In